Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study
Open Access
- 9 December 2015
- journal article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 93 (6), 1214-1218
- https://doi.org/10.4269/ajtmh.15-0033
Abstract
The standard treatment of mucosal leishmaniasis (ML) is pentavalent antimonials, agents with serious adverse effects. Alternative agents include amphotericin B deoxycholate and liposomal amphotericin B. We performed a retrospective study including 29 patients treated with liposomal amphotericin B, most of whom had comorbidities, history of previous treatment of ML, and contraindications to the use of antimonial pentavalent or amphotericin B deoxycholate. We observed a cure rate of 93.1%. Kidney failure was the most important side effect, reported in five patients (17.2%). This study showed a good efficacy and safety profile of liposomal amphotericin B in patients with ML and contraindications to the use of other agents.This publication has 23 references indexed in Scilit:
- Mucosal Leishmaniasis: An Underestimated Presentation of a Neglected DiseaseBioMed Research International, 2013
- Cutaneous and Mucocutaneous LeishmaniasisInfectious Disease Clinics of North America, 2012
- Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?The American Journal of Tropical Medicine and Hygiene, 2011
- Mucosal Leishmaniasis Caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian AmazonPLoS Neglected Tropical Diseases, 2011
- New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatmentJournal of the American Academy of Dermatology, 2010
- Sequence analysis and PCR-RFLP profiling of the hsp70 gene as a valuable tool for identifying Leishmania species associated with human leishmaniasis in BrazilInfection, Genetics and Evolution, 2010
- Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in BrazilJournal of the European Academy of Dermatology and Venereology, 2009
- Mucosal leishmaniasis: Current scenario and prospects for treatmentActa Tropica, 2008
- Treatment of Mucosal Leishmaniasis with a Lipid Formulation of Amphotericin BClinical Infectious Diseases, 2007
- Tratamento da forma mucosa de leishmaniose sem resposta a glucantime, com anfotericina B liposomalRevista da Sociedade Brasileira de Medicina Tropical, 1997